Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic drug-induced liver injury

Liver International

Volumn 33, Issue 9, 2013, Pages 1378-1385

  Ulzurrun, Eugenia ^a,b   Stephens, Camilla ^a,b   Crespo, Esperanza ^b,c   Ruiz Cabello, Francisco ^d,e   Ruiz Nuñez, Julia ^a   Saenz López, Pablo ^d,e   Moreno Herrera, Inmaculada ^a,b   Robles Díaz, Mercedes ^a,b   Hallal, Hacibe ^f   Moreno Planas, José M ^g   Cabello, Maria R ^a,b   Lucena, M Isabel ^a,b   Andrade, Raúl J ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c Facultad de Farmacia   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e Red Genómica Del Cáncer   (Spain)

^f HOSPITAL MORALES MESEGUER   (Spain)

^g HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

ABCB11; Aromatic ring structure; Canalicular transporter; Hepatotoxicity; Pharmacogenetics

Indexed keywords

ABC TRANSPORTER B11; ANTIINFECTIVE AGENT; AROMATIC CARBOXYLIC ACID; BILE SALT; BILE SALT EXPORT PUMP; CARDIOVASCULAR AGENT; CARRIER PROTEIN; MULTIDRUG RESISTANCE PROTEIN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CHEMICAL STRUCTURE; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; LIVER CELL; LIVER CELL DAMAGE; MAJOR CLINICAL STUDY; MALE; NEWBORN; RISK ASSESSMENT; STRUCTURE ANALYSIS; SYSTEMATIC REVIEW; TOXIC HEPATITIS;

ABCB11; AROMATIC RING STRUCTURE; CANALICULAR TRANSPORTER; HEPATOTOXICITY; PHARMACOGENETICS;

ACIDS, CARBOCYCLIC; ATP-BINDING CASSETTE TRANSPORTERS; DRUG-INDUCED LIVER INJURY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYDROCARBONS, AROMATIC; MALE; ODDS RATIO; PHARMACEUTICAL PREPARATIONS; POLYMORPHISM, SINGLE NUCLEOTIDE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; SPAIN;

EID: 84883777383     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12193     Document Type: Article

References (26)

1. Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001; 59: 627-35.
2. Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, Meier PJ. Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 2000; 118: 422-30.
3. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001; 69: 223-31.
4. Stieger B. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab Rev 2009; 42: 437-45.
5. Morgan RE, Trauner M, van Staden CJ, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 2010; 118: 485-500.
6. Davit-Spraul A, Gonzales E, Baussan C, Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet J Rare Dis 2009; 4: 1.
7. Stapelbroek JM, van Erpecum KJ, Klomp LW, Houwen RH. Liver disease associated with canalicular transport defects: current and future therapies. J Hepatol 2010; 52: 258-71.
8. Lam P, Soroka CJ, Boyer JL. The bile salt export pump: clinical and experimental aspects of genetic and acquired cholestatic liver disease. Semin Liver Dis 2010; 30: 125-33.
9. Pauli-Magnus C, Lang T, Meier Y, et al. Sequence analysis of bile salt export pump (ABCB11) and multidrug resistance p-glycoprotein 3 (ABCB4, MDR3) in patients with intrahepatic cholestasis of pregnancy. Pharmacogenetics 2004; 14: 91-102.
10. Meier Y, Pauli-Magnus C, Zanger UM, et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 2006; 44: 62-74.
11. Meier Y, Zodan T, Lang C, et al. Increased susceptibility for intrahepatic cholestasis of pregnancy and contraceptive-induced cholestasis in carriers of the 1331T>C polymorphism in the bile salt export pump. World J Gastroenterol 2008; 14: 38-45.
12. Lang C, Meier Y, Stieger B, et al. Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet Genomics 2007; 17: 47-60.
13. Hirano H, Kurata A, Onishi Y, et al. High-speed screening and QSAR analysis of human ATP-binding cassette transporter ABCB11 (bile salt export pump) to predict drug-induced intrahepatic cholestasis. Mol Pharm 2006; 3: 252-65.
14. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11: 272-6.
15. Andrade RJ, Lucena MI, Fernández MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129: 512-21.
16. Pachkoria K, Lucena MI, Ruiz-Cabello F, et al. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol 2007; 150: 808-15.
17. Livak KJ. SNP genotyping by the 5′-nuclease reaction. Methods Mol Biol 2003; 212: 129-47.
18. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559-75.
19. Bohan A, Boyer JL. Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Sem Liv Dis 2002; 22: 123-36.
20. Byrne JA, Strautnieks SS, Ihrke G, et al. Missense mutations and single nucleotide polymorphisms in ABCB11 impair bile salt export pump processing and function or disrupt pre-messenger RNA splicing. Hepatology 2009; 49: 553-67.
21. Dawson S, Stahl S, Paul N, Barber J, Kenna G. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 2012; 40: 130-8.
22. Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009; 49: 2001-9.
23. Clemente MI, Alvarez S, Serramía MJ, et al. Non-steroidal anti-inflammatory drugs increase the antiretroviral activity of nucleoside reverse transcriptase inhibitors in HIV type-1-infected T-lymphocytes: role of multidrug resistance protein 4. Antivir Ther 2009; 14: 1101-11.
24. Lucena MI, García-Martín E, Andrade RJ, et al. Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury. Hepatology 2010; 52: 303-12.
25. Matthews EJ, Ursem CJ, Kruhlak NL, et al. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 2009; 54: 23-42.
26. Matthews EJ, Kruhlak NL, Benz RD, et al. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities. Regul Toxicol Pharmacol 2009; 54: 43-65.